On Monday, shares of biotech Moderna Inc. (MRNA - Free Report) soared over 26% in midday trading, and closed up nearly 20% to $80 a share.
Investors were bullish on positive results from a Phase 1 study of Moderna’s coronavirus vaccine candidate. The company tested three different dosing regimens in healthy adults aged 18-55, and participants in all three groups developed antibodies against COVID-19 by day 15 after dosing.
Antibodies could be a strong indicator of immunity.
Moderna said the vaccine appears to be generally safe and well tolerated.
Going forward, Moderna expects a Phase 2 study to begin soon, and a Phase 3 test is set for July.
In other coronavirus new, Vir Biotechnology (VIR - Free Report) also announced today that it selected two potential coronavirus treatments, which will now be sent into clinical testing with GlaxoSmithKline (GSK - Free Report) .
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>